{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:09:34Z","timestamp":1788984574985,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.prro.2025.05.004","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T12:05:20Z","timestamp":1747915520000},"page":"610-624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Combining Radiation Therapy With Immune Checkpoint Inhibitors for the Management of Muscle-Invasive Bladder Cancer: A Comprehensive Systematic Review From the Y-ECI ROSC EORTC Group"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5374-8851","authenticated-orcid":false,"given":"V\u00e9rane","family":"Achard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda","family":"Abdel-Aty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Duque-Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Bebek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiuri E.","family":"Kroese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miha","family":"Orazem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Dirix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2025.05.004_bib0001","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.prro.2025.05.004_bib0002","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2003.05.101","article-title":"Radical cystectomy for bladder cancer today \u2013 A homogeneous series without neoadjuvant therapy","volume":"21","author":"Madersbacher","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.05.004_bib0003","unstructured":"EAU guidelines. 2024. https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer. Accessed January 01, 2024."},{"key":"10.1016\/j.prro.2025.05.004_bib0004","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.prro.2025.05.004_bib0005","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bju.13900","article-title":"Clinical and patient-reported outcomes of SPARE \u2013 a randomised feasibility study of selective bladder preservation versus radical cystectomy","volume":"120","author":"Huddart","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.prro.2025.05.004_bib0006","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijrobp.2007.06.030","article-title":"Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center","volume":"70","author":"Kotwal","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.004_bib0007","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijrobp.2009.04.050","article-title":"A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK","volume":"77","author":"Munro","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.004_bib0008","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clon.2021.03.023","article-title":"Image-guided adaptive radiotherapy for bladder cancer","volume":"33","author":"Kong","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.prro.2025.05.004_bib0009","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2025.05.004_bib0010","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.ijrobp.2021.03.001","article-title":"Long-term outcomes of radical radiation therapy with hypoxia modification with biomarker discovery for stratification: 10-year update of the BCON (Bladder Carbogen Nicotinamide) phase 3 randomized trial (ISRCTN45938399)","volume":"110","author":"Song","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.004_bib0011","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","article-title":"Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials","volume":"22","author":"Choudhury","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.05.004_bib0012","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/0360-3016(79)90062-2","article-title":"Pre-operative irradiation of T3-carcinoma in bilharzial bladder: a comparison between hyperfractionation and conventional fractionation","volume":"5","author":"Awwad","year":"1979","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.004_bib0013","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0022-5347(01)65047-X","article-title":"Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: A phase III intergroup study","volume":"157","author":"Smith","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2025.05.004_bib0014","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000474069","article-title":"A prospective randomized study of preoperative irradiation with cystectomy or cystectomy alone for invasive bladder carcinoma","volume":"9","author":"Anderstr\u00f6m","year":"1983","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2025.05.004_bib0015","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/jso.2930090410","article-title":"Five-year follow-up results of a collaborative study of therapies for carcinoma of the bladder","volume":"9","author":"Slack","year":"1977","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.prro.2025.05.004_bib0016","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0022-5347(17)60895-4","article-title":"Results of a clinical trial of surgery and radiation in stages II and 3 carcinoma of the bladder","volume":"108","author":"Blackard","year":"1972","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2025.05.004_bib0017","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0022-5347(17)47119-9","article-title":"Randomized trial of cystectomy with or without preoperative radiotherapy for carcinoma of the bilharzial bladder","volume":"134","author":"Ghoneim","year":"1985","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2025.05.004_bib0018","unstructured":"Bladder cancer: diagnosis and management, NICE guideline [NG2]. Accessed February 25, 2015. https:\/\/www.nice.org.uk\/guidance\/ng2\/chapter\/1-Recommendations#follow-up-after-treatment-for-muscle-invasive-bladder-cancer."},{"key":"10.1016\/j.prro.2025.05.004_bib0019","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.prro.2025.05.004_bib0020","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2025.05.004_bib0021","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00345-020-03440-4","article-title":"Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response","volume":"39","author":"Daro-Faye","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.prro.2025.05.004_bib0022","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.prro.2025.05.004_bib0023","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12885-019-6503-6","article-title":"Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer \u2013 study protocol of a prospective, single arm, multicenter phase II trial (RACE IT)","volume":"20","author":"Schmid","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prro.2025.05.004_bib0024","volume":"33","author":"Schmid","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.prro.2025.05.004_bib0025","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.euo.2023.09.011","article-title":"Pembrolizumab with chemoradiation as treatment for muscle-invasive bladder cancer: analysis of safety and efficacy of the PCR-MIB phase 2 clinical trial (ANZUP 1502)","volume":"7","author":"Weickhardt","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.prro.2025.05.004_bib0026","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ijrobp.2020.12.033","article-title":"Phase 1 trial of atezolizumab plus trimodal therapy in patients with localized muscle-invasive bladder cancer","volume":"110","author":"Marcq","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.004_bib0027","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1200\/JCO.2021.39.15_suppl.4504","article-title":"Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): a multicenter phase 2 trial","volume":"39","author":"Balar","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.05.004_bib0028","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.eururo.2022.07.009","article-title":"Phase 1 study of chemoradiotherapy combined with nivolumab \u00b1 ipilimumab for the curative treatment of muscle-invasive bladder cancer","volume":"82","author":"de Ruiter","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2025.05.004_bib0029","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1200\/JCO.2022.40.6_suppl.506","article-title":"NEXT: a single-arm, phase 2, open-label study of adjuvant nivolumab after completion of chemo-radiation therapy in patients with localized muscle-invasive bladder cancer","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.05.004_bib0030","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.ijrobp.2022.07.475","article-title":"INTACT (S\/N1806): phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer\u2014Toxicity update on first 213 patients","volume":"114","author":"Singh","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.004_bib0031","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS5093","article-title":"Phase III study of pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus CRT alone for patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-992","volume":"38","author":"Balar","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.05.004_bib0032","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.euf.2022.12.012","article-title":"Efficacy and safety of pembrolizumab (MK-3475) in combination with chemoradiotherapy versus chemoradiotherapy alone in muscle-invasive bladder cancer: the MK-3475-992\/KEYNOTE-992 trial","volume":"9","author":"Tissot","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.prro.2025.05.004_bib0033","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1200\/JCO.2023.41.16_suppl.4509","article-title":"Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): a multicenter phase 2 trial","volume":"41","author":"Economides","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.05.004_bib0034","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006551","article-title":"Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023","volume":"11","author":"Joshi","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.prro.2025.05.004_bib0035","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.ijrobp.2023.11.024","article-title":"Phase II trial of concurrent nivolumab and radiation therapy for muscle-invasive bladder cancer of older or chemotherapy-ineligible patients","volume":"118","author":"Vaishampayan","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.004_bib0036","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1200\/JCO.2021.39.15_suppl.4505","article-title":"Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial","volume":"39","author":"Garcia del Muro","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.05.004_bib0037","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ijrobp.2018.04.070","article-title":"Dose-limiting urinary toxicity with pembrolizumab combined with weekly hypofractionated radiation therapy in bladder cancer","volume":"101","author":"Tree","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.004_bib0038","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijrobp.2023.05.013","article-title":"Efficacy and safety of bladder preservation therapy in combination with atezolizumab and radiation therapy (BPT-ART) for invasive bladder cancer: interim analysis from a multicenter, open-label, prospective phase 2 trial","volume":"117","author":"Kimura","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.004_bib0039","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1200\/JCO.2022.40.6_suppl.517","article-title":"Safety lead-in of phase II SBRT and durvalumab with or without tremelimumab for unresectable and cisplatin-ineligible, locally advanced or metastatic bladder cancer","volume":"40","author":"Kundu","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.05.004_bib0040","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1200\/JCO.2022.40.16_suppl.4588","article-title":"Efficacy and safety of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer: an interim analysis of the ATEZOBLADDERPRESERVE phase II trial (SOGUG-2017-A-IEC(VEJ)-4)","volume":"40","author":"Vazquez-Estevez","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.05.004_bib0041","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.05.004_bib0042","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2025.05.004_bib0043","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.05.004_bib0044","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2025.05.004_bib0045","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2025.05.004_bib0046","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.05.004_bib0047","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2025.05.004_bib0048","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1470-2045(24)00100-1","article-title":"Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial","volume":"25","author":"Machiels","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.05.004_bib0049","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.05.004_bib0050","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.446","article-title":"Randomised phase II trial of adaptive image guided radiotherapy in muscle invasive bladder cancer: late toxicity and cancer outcomes","volume":"41","author":"Huddart","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.05.004_bib0051","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN guidelines\u00ae insights: bladder cancer, version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.prro.2025.05.004_bib0052","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.radonc.2018.05.022","article-title":"Outcomes of radiosensitisation in elderly patients with advanced bladder cancer","volume":"129","author":"Christodoulou","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.05.004_bib0053","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2025.05.004_bib0054","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/j.ijrobp.2022.07.1132","article-title":"Stereotactic radiotherapy boost as part of tri-modality treatment for bladder preservation in patients with muscle-invasive bladder cancer","volume":"114","author":"Qin","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.004_bib0055","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.2217\/fon-2022-0380","article-title":"A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial","volume":"18","author":"Satkunasivam","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.prro.2025.05.004_bib0056","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.eururo.2023.01.017","article-title":"A phase 1 trial of durvalumab in combination with bacillus calmette-guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive Non-muscle-Invasive bladder cancer: the Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER study","volume":"83","author":"Hahn","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2025.05.004_bib0057","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2024.09.006","article-title":"Dose-escalated adaptive radiotherapy for bladder cancer: results of the phase 2 RAIDER randomised controlled trial","volume":"87","author":"Huddart","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2025.05.004_bib0058","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1016\/j.ijrobp.2011.05.051","article-title":"Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience","volume":"82","author":"Tunio","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.004_bib0059","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.ijrobp.2021.08.016","article-title":"Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: Single-institution experience. Int J Radiat Oncol Biol Phys;2012;82:e457-e462","volume":"111","author":"Zietman","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.004_bib0060","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.23.02718","article-title":"Benefit of whole-pelvis radiation for patients with muscle-invasive bladder cancer: an inverse probability treatment weighted analysis","volume":"43","author":"Marcq","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.05.004_bib0061","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187985002500147X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187985002500147X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:45:48Z","timestamp":1761900348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187985002500147X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S187985002500147X"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2025.05.004","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining Radiation Therapy With Immune Checkpoint Inhibitors for the Management of Muscle-Invasive Bladder Cancer: A Comprehensive Systematic Review From the Y-ECI ROSC EORTC Group","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2025.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Radiation Oncology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}